期刊文献+

肿瘤预定位反义显像的应用研究和进展(文献综述) 被引量:1

下载PDF
导出
出处 《放射免疫学杂志》 CAS 2009年第3期256-257,共2页 Journal of Radioimmanology
基金 国家自然科学基金资助项目(编号30770601)
  • 相关文献

参考文献3

二级参考文献7

共引文献10

同被引文献22

  • 1夏忠军,王风华,黄慧强,骆卉妍,李宇红,林桐榆,姜文奇,管忠震.含美罗华方案治疗B细胞性惰性淋巴瘤34例报告[J].癌症,2006,25(4):490-494. 被引量:9
  • 2Kohler G,Milsteln C.Continuous cultures of fused cells secreting antibody of predefined apecifieily[J].J Immunol,2005,174(5):2453.
  • 3Mellstedt H.Monoclonal antibodies in human cancer[J].Drugs Today (Barc),2003,39 Supple C:1-16.
  • 4Feuqier P,van Hoof A,Sebban C,et al.Long-term results of the R-CHOP study of elderly patients with diffuse large B-cell lymphoma:A study by the Group Etude des lymphoma de LAdute[J].J Clin Oncol,2005,18(23):4117-4126.
  • 5Vose JM,Link BK,Gross BML,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389-397.
  • 6Lundin A,Porwit-MacDonald E,Rossmann D,et al.Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody,CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia[J].Leukema,2004,18(3):484-490.
  • 7Knapp FF.Rhenium-188-a generator-derived radioisotope for cancer therapy[J].Cancer Biother Radiopharm,1998,13(5):337-349.
  • 8Wagner HN,Wiseman GA,Marm MCS,et al.Administration guidelines for radioimmunotherapy of non-Hodgldn's lymphoma with90Y-labelled anti-CD20 monoclonal antibody[J].J Nucl Med,2002,43(2):267-272.
  • 9Kaminski MS,Zelenetz AD,Press OW,et al.Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformedlow-grade B-cell non-Hodgkin's lymphomas[J].J Clin Oncol,2001,19(19):3918-3928.
  • 10Witzig TE,White CA,Gordon LI.Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade,follicular,or transformed non-Hodgkin's lymphoma[J].J Clin Oncol,2003,21(7):1263-1270.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部